Artemis Medicare Services growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+15.4%+6.6%+19.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+24.0%+14.4%+41.3%
+31.4%+15.4%+46.8%
+26.2%+67.2%+29.3%
+22.2%+48.3%+25.3%
+5.2%+39.7%+7.4%
+11.5%+85.5%+11.5%
−9.4%+33.8%−14.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ARTEMISMED₹297.95

Artemis Medicare Services Limited

· Pharma & Health
₹ CrorePeersINDRAMEDCOSHALBYGKSLGPTHEALTHLOTUSEYEDRAGARWQKMCSHILKOVAIMcap ₹4,717 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+19.1+6.6+15.4—
EBITDA Growth—+41.3+14.4+24.0—
EBIT Growth—+46.8+15.4+31.4—
Net Income Growth—+29.3+67.2+26.2—
EPS Growth—+25.3+48.3+22.2—
Total Assets Growth—+7.4+39.7+5.2—
Total Equity Growth—+11.5+85.5+11.5—
Cash from Operations Growth—-14.4+33.8-9.4—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.